FindTrial
Sign In

Evaluation platinum based chemotherapy before surgery in treatment of patients with triple-negative breast cancer at a rural tertiary care hospital

Evaluation of anthracycline chemotherapy followed by weekly carboplatin plus paclitaxel on the neoadjuvant treatment of patients with triple-negative breast cancer at a tertiary care hospital in a rural setting - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/059751
Enrollment
39
Registered
2023-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Jawaharlal Nehru Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ER – tumors less than 1% PR – tumors less than 1% Her2 neu – tumors IHC staining 0 to 1+, (FISH) ratio ECOG Stage 2,3 breast cancer T size > 20 mm Biopsy proven invasive breast cancer Not previously treated with taxanes, anthracyclines or carboplatin Written consent Adequate renal, hepatic and bone marrow reserve LVEF > 55%

Exclusion criteria

Exclusion criteria: Age ER + tumors PR + tumors Her2 neu + tumors ECOG > 2 Stage 4 breast cancer T size ER > 1%, PR > 1% , Her2 Neu 3+

Design outcomes

Primary

MeasureTime frame
progression-free survival at 1 year Timepoint: progression-free survival at 1 year—

Secondary

MeasureTime frame
Pathological complete responseTimepoint: After surgery at 24 weeks of start of chemotherapy—

Countries

India

Contacts

Public ContactKaran Sood

Jawaharlal Nehru Medical College

amolpgi@yahoo.co.in9823311569

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026